Karin Hehenberger
Director/Board Member chez AADI BIOSCIENCE, INC.
Fortune : 9 801 $ au 31/03/2024
Profil
Karin M.
Hehenberger was the founder of Lyfebulb LLC, a company founded in 2014, where she held the title of Chief Executive Officer & Director.
Dr. Hehenberger is also the founder of Lyfebulb Holdings, Inc...
Dr. Hehenberger's current jobs include being an Independent Director at Diamyd Medical AB, a Director at Amal Therapeutics SA, a Director at Rolf Lufts Stiftelse Foer Diabetesforskning, a Director at Aadi Subsidiary, Inc., a Director at AnaCardio AB, and an Independent Director at Aadi Bioscience, Inc. starting in 2021.
Dr. Hehenberger's former jobs include being a Senior Director-Scientific Communications at Oldtech, Inc., a Director at Lighthouse International, a Director at Newron Sweden AB, a Director at American Diabetes Association, a Partner & Investment Director at Scandinavian Life Science Ventures AB from 2005 to 2008, a Director at Atlas Antibodies AB, a VP-Metabolics Strategy & Business Development at Johnson & Johnson, an Executive Vice President-Scientific Affairs at Fortress Biotech, Inc. in 2013, a Consultant at McKinsey & Co., Inc., a Senior Vice President-Strategic Alliances at JDRF International, a Post-Doctoral Fellow at Joslin Diabetes Center, Inc., and a SVP-Medical Affairs & Corporate Communications at Immune Pharmaceuticals, Inc. Dr. Hehenberger obtained a doctorate degree from Karolinska Institutet.
Dr. Hehenberger is also the founder of Lyfebulb Holdings, Inc...
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/08/2023 | 10 000 ( 0,01% ) | 9 801 $ | 31/03/2024 | |
AADI BIOSCIENCES, INC.
-.--% | 15/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Karin Hehenberger
| Sociétés | Poste | Début |
|---|---|---|
| DIAMYD MEDICAL AB | Director/Board Member | 28/04/2021 |
| AADI BIOSCIENCE, INC. | Director/Board Member | 26/08/2021 |
AnaCardio AB
 AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Director/Board Member | - |
Aadi Subsidiary, Inc.
 Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | Director/Board Member | - |
| Rolf Lufts Stiftelse Foer Diabetesforskning | Director/Board Member | - |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Director/Board Member | - |
Anciens postes connus de Karin Hehenberger
| Sociétés | Poste | Fin |
|---|---|---|
| FORTRESS BIOTECH, INC. | Chief Tech/Sci/R&D Officer | 05/11/2013 |
Lighthouse International
 Lighthouse International Personnel ServicesCommercial Services Lighthouse International provides rehabilitation, education, research and advocacy services. The company has been more than 105 years charge in the fight against vision loss through prevention, treatment and empowerment. Their founders, winifred and edith holt, blazed a trail of firsts and opened up new doors of opportunity for people without sight. Today they proud to continue the Holt legacy on behalf of all those who look to the Lighthouse as a beacon of hope today. The company was founded in 1905 and is headquartered in New York, N | Director/Board Member | 18/09/2013 |
Scandinavian Life Science Ventures AB
 Scandinavian Life Science Ventures AB Investment ManagersFinance SLS Invest AB (SLS Invest) is a venture capital firm wholly-owned by Sjätte AP-fonden. The firm was established in 2007 and is headquartered in Stockholm, Sweden, with a branch office in Copenhagen, Denmark. | Private Equity Investor | 01/01/2008 |
| ░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Karin Hehenberger
| Karolinska Institutet | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| FORTRESS BIOTECH, INC. | Health Technology |
| DIAMYD MEDICAL AB | Health Technology |
| AADI BIOSCIENCE, INC. | Health Technology |
| Entreprise privées | 15 |
|---|---|
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Lighthouse International
Lighthouse International Personnel ServicesCommercial Services Lighthouse International provides rehabilitation, education, research and advocacy services. The company has been more than 105 years charge in the fight against vision loss through prevention, treatment and empowerment. Their founders, winifred and edith holt, blazed a trail of firsts and opened up new doors of opportunity for people without sight. Today they proud to continue the Holt legacy on behalf of all those who look to the Lighthouse as a beacon of hope today. The company was founded in 1905 and is headquartered in New York, N | Commercial Services |
Newron Sweden AB
 Newron Sweden AB Pharmaceuticals: MajorHealth Technology Newron Sweden AB is a biopharmaceutical company engaged in the development of novel therapies for the treatment of disorders of the central nervous systems. The company was founded by Jonas Cristopher Frisen and Ann Marie Janson in 1998 and is headquartered in Stockholm, Sweden. | Health Technology |
American Diabetes Association
 American Diabetes Association Miscellaneous Commercial ServicesCommercial Services American Diabetes Association provides diabetes related medical services. It funds research, publishes scientific findings, provides information and other services to people with diabetes, their families, health professionals and the public. The company was founded in 1940 and is headquartered in Alexandria, VA. | Commercial Services |
Scandinavian Life Science Ventures AB
Scandinavian Life Science Ventures AB Investment ManagersFinance SLS Invest AB (SLS Invest) is a venture capital firm wholly-owned by Sjätte AP-fonden. The firm was established in 2007 and is headquartered in Stockholm, Sweden, with a branch office in Copenhagen, Denmark. | Finance |
JDRF International
 JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Commercial Services |
Atlas Antibodies AB
 Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
Joslin Diabetes Center, Inc.
 Joslin Diabetes Center, Inc. Pharmaceuticals: MajorHealth Technology Joslin Diabetes Center, Inc. is a non-profit organization, which engages in the development of pharmaceuticals for diabetes. It provides adult care, pediatric care, eye care, and education programs and classes. The company was founded by Elliott P. Joslin in 1893 and is headquartered in Boston, MA. | Health Technology |
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
| Rolf Lufts Stiftelse Foer Diabetesforskning | |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | Health Technology |
Lyfebulb LLC
 Lyfebulb LLC Internet Software/ServicesTechnology Services Lyfebulb LLC is an innovation accelerator that works with patient communities and the healthcare industry to generate insights and build new solutions to reduce the burden of living with chronic disease. The private company is based in New York, NY. The company operates across 12 disease states and has two digital patient communities, including ibdlyfe. The company's mission is to reduce the burden of living with chronic disease through the power of the patient. Lyfebulb was founded by Riccardo Braglia, Stephen P. Squinto, and Karin M. Hehenberger, who has been the CEO since incorporation. | Technology Services |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Health Technology |
